CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Sequence variations in PCSK9, low LDL, and protection against coronary heart disease Radial Versus Femoral Access for Rotational Atherectomy: A UK Observational Study of 8622 Patients Heart failure with preserved ejection fraction: from mechanisms to therapies Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease: analysis from the EXCEL trial

Original Research2019 Aug 7;40(30):2482-2491.

JOURNAL:Eur Heart J. Article Link

Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis

Vromman A, Ruvkun V, Shvartz E et al. Keywords: arterial remodelling; atherosclerosis; inflammation; interleukin-1

ABSTRACT


AIMS - Targeting interleukin-1 (IL-1) represents a novel therapeutic approach to atherosclerosis. CANTOS demonstrated the benefits of IL-1β neutralization in patients post-myocardial infarction with residual inflammatory risk. Yet, some mouse data have shown a prominent role of IL-1α rather than IL-1β in atherosclerosis, or even a deleterious effect of IL-1 on outward arterial remodelling in atherosclerosis-susceptible mice. To shed light on these disparate results, this study investigated the effect of neutralizing IL-1α or/and IL-1β isoforms starting either early in atherogenesis or later in ApoE-/- mice with established atheroma.


METHODS AND RESULTS - The neutralization of IL-1α or of both IL-1 isoforms impaired outward remodelling during early atherogenesis as assessed by micro-computed tomographic and histologic assessment. In contrast, the neutralization of IL-1β did not impair outward remodelling either during early atherogenesis or in mice with established lesions. Interleukin-1β inhibition promoted a slant of blood monocytes towards a less inflammatory state during atherogenesis, reduced the size of established atheromata, and increased plasma levels of IL-10 without limiting outward remodelling of brachiocephalic arteries.


CONCLUSION - This study established a pivotal role for IL-1α in the remodelling of arteries during early experimental atherogenesis, whereas IL-1β drives inflammation during atherogenesis and the evolution of advanced atheroma in mice.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019.